MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 555135 | Name: Fexuprazan
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fexuprazan, also known as Abeprazan and DWP14012, is an acid pump inhibitor. Fexuprazan inhibits H+, K+- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Proton pump inhibitors (PPIs) are a mainstay treatment for acid peptic disorders such as gastroesophageal reflux disease (GERD).

Chemical Structure

Fexuprazan
Fexuprazan
CAS#1902954-60-2 (free base)

Theoretical Analysis

MedKoo Cat#: 555135

Name: Fexuprazan

CAS#: 1902954-60-2 (free base)

Chemical Formula: C19H17F3N2O3S

Exact Mass: 410.0912

Molecular Weight: 410.41

Elemental Analysis: C, 55.60; H, 4.18; F, 13.89; N, 6.83; O, 11.69; S, 7.81

Price and Availability

Size Price Availability Quantity
5mg USD 950.00 2 Weeks
10mg USD 1,650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
1902954-87-3 (HCl) 1902954-60-2 (free base)
Synonym
Abeprazan; DWP14012; DWP-14012; DWP 14012; Fexuprazan;
IUPAC/Chemical Name
1-[5-(2,4-difluorophenyl)-1-(3-fluorobenzene-1-sulfonyl)-4-methoxy-1H-pyrrol-3-yl]-N-methylmethanamine
InChi Key
1138549-36-6
InChi Code
InChI=1S/C19H17F3N2O3S/c1-23-10-12-11-24(28(25,26)15-5-3-4-13(20)8-15)18(19(12)27-2)16-7-6-14(21)9-17(16)22/h3-9,11,23H,10H2,1-2H3
SMILES Code
CNCC1=CN(S(=O)(C2=CC=CC(F)=C2)=O)C(C3=CC=C(F)C=C3F)=C1OC
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 410.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Shin W, Yang AY, Park H, Lee H, Yoo H, Kim A. A Comparative Pharmacokinetic Study of Fexuprazan 10 mg: Demonstrating Bioequivalence with the Reference Formulation and Evaluating Steady State. Pharmaceuticals (Basel). 2023 Aug 11;16(8):1141. doi: 10.3390/ph16081141. PMID: 37631056; PMCID: PMC10458111. 2: Ramani A, Merchant A, Cash BD. Review of the clinical development of fexuprazan for gastroesophageal reflux-related disease. Eur J Clin Pharmacol. 2023 Aug;79(8):1023-1029. doi: 10.1007/s00228-023-03521-4. Epub 2023 Jun 22. PMID: 37344679. 3: Yang AY, Yoo H, Shin W, Lee YS, Lee H, Kim SE, Kim A. Size-reduced fexuprazan 20 mg demonstrated the optimal bioavailability and bioequivalence with the reference formulation. Transl Clin Pharmacol. 2023 Mar;31(1):40-48. doi: 10.12793/tcp.2023.31.e3. Epub 2023 Mar 22. PMID: 37034124; PMCID: PMC10079506. 4: Oh J, Yang E, Jang IJ, Lee H, Yoo H, Chung JY, Lee S, Oh J. Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium- Competitive Inhibitor, and Aspirin, in Healthy Subjects. Pharmaceutics. 2023 Feb 7;15(2):549. doi: 10.3390/pharmaceutics15020549. PMID: 36839870; PMCID: PMC9958674. 5: Kim GH, Choi MG, Kim JI, Lee ST, Chun HJ, Lee KL, Choi SC, Jang JY, Lee YC, Kim JG, Kim KB, Shim KN, Sohn CI, Kim SK, Kim SG, Jang JS, Kim N, Jung HY, Park H, Huh KC, Lee KJ, Hong SJ, Baek S, Han JJ, Lee OY. Efficacy and Safety of Fexuprazan in Patients with Acute or Chronic Gastritis. Gut Liver. 2023 Feb 15. doi: 10.5009/gnl220457. Epub ahead of print. PMID: 36789577. 6: Lee KN, Lee OY, Chun HJ, Kim JI, Kim SK, Lee SW, Park KS, Lee KL, Choi SC, Jang JY, Kim GH, Sung IK, Park MI, Kwon JG, Kim N, Kim JJ, Lee ST, Kim HS, Kim KB, Lee YC, Choi MG, Lee JS, Jung HY, Lee KJ, Kim JH, Chung H. Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis. World J Gastroenterol. 2022 Nov 28;28(44):6294-6309. doi: 10.3748/wjg.v28.i44.6294. PMID: 36504556; PMCID: PMC9730436. 7: Kim MS, Lee N, Lee A, Chae YJ, Chung SJ, Lee KR. Model-Based Prediction of Acid Suppression and Proposal of a New Dosing Regimen of Fexuprazan in Humans. Pharmaceuticals (Basel). 2022 Jun 3;15(6):709. doi: 10.3390/ph15060709. PMID: 35745628; PMCID: PMC9230547. 8: Jeong YS, Kim MS, Lee N, Lee A, Chae YJ, Chung SJ, Lee KR. Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans. Pharmaceutics. 2021 May 29;13(6):813. doi: 10.3390/pharmaceutics13060813. PMID: 34072547; PMCID: PMC8229463. 9: Scarpignato C, Hunt RH. Editorial: acid suppression with potassium- competitive acid blockers dismissing genotype concerns. Aliment Pharmacol Ther. 2021 Jan;53(1):187-188. doi: 10.1111/apt.16139. PMID: 33333607. 10: Hwang JG, Lee S. Editorial: acid suppression with potassium-competitive acid blockers-dismissing genotype concerns. Authors' reply. Aliment Pharmacol Ther. 2021 Jan;53(1):189. doi: 10.1111/apt.16158. PMID: 33333601. 11: Hwang JG, Jeon I, Park SA, Lee A, Yu KS, Jang IJ, Lee S. Pharmacodynamics and pharmacokinetics of DWP14012 (fexuprazan) in healthy subjects with different ethnicities. Aliment Pharmacol Ther. 2020 Dec;52(11-12):1648-1657. doi: 10.1111/apt.16131. Epub 2020 Oct 27. PMID: 33111337. 12: Sunwoo J, Oh J, Moon SJ, Ji SC, Lee SH, Yu KS, Kim HS, Lee A, Jang IJ. Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2018 Jul;48(2):206-218. doi: 10.1111/apt.14818. Epub 2018 Jun 4. PMID: 29863280.